1
|
Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupret M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, Archambaud B, Belhechmi S, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, Le Teuff G, Derosa L, Marabelle A, VAN Dorp J, VAN Dijk N, van der Heijden MS, Besse B, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Loriot Y. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov 2022; 12:2280-2307. [PMID: 35929803 DOI: 10.1158/2159-8290.cd-22-0201] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 06/21/2022] [Accepted: 08/02/2022] [Indexed: 11/16/2022]
Abstract
Biomarkers guiding the neoadjuvant use of immune checkpoint inhibitors (ICBs) are needed for patients with localized muscle invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline, and the induction of tertiary lymphoid structures post-pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Cedric Lebacle
- Bicêtre Hospital APHP University Paris Saclay, LE KREMLIN BICETRE, France
| | | | | | | | | | | | | | | | | | | | | | | | | | - Pierre Ly
- Gustave Roussy Cancer Campus (GRCC), Villejuif, France
| | | | | | | | | | | | | | | | - Jacques Bou Khalil
- Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Florent Ginhoux
- Singapore Immunology Network Agency for Science, Technology, and Research, Singapore, Singapore
| | - Gwenael Le Teuff
- Gustave Roussy, Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Lisa Derosa
- Gustave Roussy Cancer Center, Villejuif, France
| | | | | | - Nick VAN Dijk
- The Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | | | | | - Miriam Merad
- Precision Immunology Institute, New York, NY, United States
| | | | | | | | | |
Collapse
|